Orthovita gets Nasdaq listing but stays with Easdaq:
This article was originally published in Clinica
Orthovita, an orthopaedic biomaterials company, has gone onto the Nasdaq US high technology market in addition to its listing on the European Easdaq. The shares opened at $6.50 before sliding down by around $1. The Malvern, Pennsylvania-based company is looking to broaden its US investor base while maintaining its European investors. The company plans a European launch of its VITOSS Scaffold cancellous bone resorbable calcium phosphate product in Europe next month.
You may also be interested in...
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.